Boehringer Ingelheim and partners accelerate development of first-of-its-kind gene therapy for cystic fibrosis patients

Boehringer Ingelheim has exercised IP Group’s right to choose the intellectual property rights of the research results of the British Cystic Fibrosis Gene Therapy Alliance, and Oxford Biomedical Company’s right to choose the intellectual property rights of its lentiviral vector technology.

Ingelheim, Germany, October 22, 2021/PRNewswire/ - Boehringer Ingelheim, IP Group, British Cystic Fibrosis Gene Therapy Consortium (GTC, composed of researchers from Imperial College London, University of Oxford and University of Edinburgh) And Oxford Biopharmaceuticals (OXB), recently announced that Boehringer Ingelheim has exercised its partners’ intellectual property and proprietary technology options to advance and further accelerate the development of potential new treatments for patients with cystic fibrosis

Cystic fibrosis is a rare, progressive, and life-threatening disease that can cause severe lung dysfunction and persistent infections, affecting 70,000 people worldwide

Professor Eric Alton, the coordinator of GTC, said: “The new lung targeting technology we have developed shows high gene transfer efficiency in preclinical models and provides the possibility of repeated administration to maintain the therapeutic effect.

Dr.

John Dawson, CEO of Oxford Biomedica, said: "Since 2018, we are very happy to collaborate with Boehringer Ingelheim, IP Group and GTC

Pursuant to the terms of the options and license agreement originally announced with Boehringer Ingelheim in August 2018, Boehringer Ingelheim will pay the option exercise fee, recent, development success, registration and sales milestone payments, and payment based on GTC to IP Group on behalf of GTC.

David Ramsden, CEO of the Cystic Fibrosis Trust, said: “Boehringer Ingelheim is committed to the next stage of gene therapy development for cystic fibrosis patients

About Boehringer Ingelheim

Boehringer Ingelheim is committed to researching breakthrough therapies aimed at improving the health of humans and animals

The British Cystic Fibrosis Gene Therapy Consortium (GTC) is composed of researchers from Imperial College London, Oxford University and Edinburgh University

For more details, please visit.

Health Innovation Challenge Fund

The Health Innovation Challenge Fund is a financing cooperation jointly established by the Weikang Trust Foundation and the Ministry of Health.

About Oxford Biomedical Corporation

Oxford Biopharmaceuticals (London Stock Exchange: OXB) is a world-leading gene and cell therapy group.

About cystic fibrosis

Cystic fibrosis is a genetic disease caused by defective genes

About the Cystic Fibrosis Trust

The Cystic Fibrosis Trust is the only charity in the UK dedicated to fighting for more life opportunities for cystic fibrosis patients